一例采用抗表皮生长因子受体抗体联合化疗治疗的阴茎鳞状细胞癌。
A case of penile squamous cell carcinoma treated with a combination of antiepidermal growth factor receptor antibody and chemotherapy.
机构信息
Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
出版信息
Anticancer Drugs. 2014 Jan;25(1):123-5. doi: 10.1097/CAD.0000000000000024.
Our previous study showed that the features of epidermal growth factor receptor (EGFR)-RAS signaling in penile squamous cell carcinoma (SCC) suggested potential benefits of anti-EGFR monoclonal antibodies (mAbs) for penile SCC. Here, we report, for the first time, a combination of nimotuzumab (an EGFR mAb) with chemotherapy that resulted in a partial response in a 44-year-old patient with penile SCC, who developed bilateral inguinal node metastasis after primary partial penile amputation. The literature of case reports of anti-EGFR mAbs in penile SCC was also reviewed.
我们之前的研究表明，阴茎鳞癌（SCC）中表皮生长因子受体（EGFR）-RAS 信号的特征表明抗 EGFR 单克隆抗体（mAb）对阴茎 SCC 可能有益。在这里，我们首次报告了尼妥珠单抗（一种 EGFR mAb）联合化疗在一名 44 岁的阴茎 SCC 患者中的应用，该患者在原发性部分阴茎截肢后出现双侧腹股沟淋巴结转移。还回顾了抗 EGFR mAb 治疗阴茎 SCC 的病例报告文献。
Zotero 插件